Estimaciones de analistas de Wall Street para CEL-SCI Corporation (CVM): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 6 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 6 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-12-23 | |||
| 2026-08-14 | $-0.47 | ||
| 2026-05-18 | $-0.67 | ||
| 2026-02-17 | $-0.68 | ||
| 2025-12-29 | $-0.76 | ||
| 2025-08-14 | $-1.36 | ||
| 2025-05-14 | $-2.40 | ||
| 2025-02-12 | $-3.30 |
Ratios de valoración
| Precio / Valor contable | 1.64 |
| EV / EBITDA | -1.71 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $285055 | $69020 | $476556 | $462754 | $558664 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $17445 | $633000 | $10914 | $12659 | $17.8M | 0 | 0 | $22.5M | $4.0M | $15.9M |
| Beneficio Bruto | $267610 | -$563980 | $465642 | $450095 | -$17.3M | 0 | 0 | -$22.5M | -$4.0M | -$15.9M |
| I+D | $19.4M | $15.6M | $9.4M | $12.7M | $17.8M | $23.1M | $25.4M | $22.5M | $18.2M | $15.9M |
| Generales y Administrativos | $6.5M | $5.8M | $7.8M | $8.0M | $11.7M | $13.1M | $10.7M | $9.0M | $4.2M | $8.9M |
| Gastos Operativos | $25.6M | $21.3M | $16.8M | $20.2M | $11.7M | $36.2M | $36.1M | $9.0M | $22.4M | $8.9M |
| Beneficio Operativo | -$25.6M | -$21.3M | -$16.8M | -$20.2M | -$29.0M | -$36.2M | -$36.1M | -$31.5M | -$26.4M | -$24.8M |
| EBITDA | -$9.1M | -$9.7M | -$16.1M | -$19.7M | -$26.8M | -$33.0M | -$31.8M | -$29.3M | -$22.2M | -$20.9M |
| Gastos por Intereses | 0 | $4.0M | 0 | $1.8M | $1.0M | $1.1M | $1.1M | $675416 | $745673 | $648944 |
| Beneficio Antes de Impuestos | -$11.5M | -$14.4M | -$31.8M | -$22.1M | -$30.3M | -$36.4M | -$36.7M | -$32.4M | -$26.9M | -$25.4M |
| Impuestos | -$14.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$11.5M | -$14.4M | -$31.8M | -$24.7M | -$30.3M | -$36.4M | -$36.7M | -$32.4M | -$26.9M | -$25.4M |
| BPA | $-62.70 | $-1638.00 | $-1685.10 | $-21.60 | $-24.71 | $-27.89 | $-26.16 | $-21.83 | $-13.50 | $-6.27 |
| BPA Diluido | $-62.40 | $-1638.00 | $-1685.10 | $-21.60 | $-24.71 | $-27.86 | $-26.16 | $-21.83 | $-13.50 | $-6.27 |
| Acciones en Circulación (Diluidas) | $184165 | $8769 | $18894 | $1.1M | $1.2M | $1.4M | $1.4M | $1.5M | $2.0M | $4.1M |
Precio
| Precio | $1.48 |
| Capitalización | $10M |
| Bolsa | AMEX |
| País | US |
Empresas relacionadas: ALGS · BRNS · FGEN · INMB · KZR · MRSN · OKUR
Explorar sector: Healthcare · Biotechnology
Más secciones de CVM: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones